Clinical genitourinary cancer最新文献

{"title":"Aggressive Paratesticular Spindle Cell Rhabdomyosarcoma in an Adult: A Rare Case and Review of Reported Adult Cases","authors":"İsmail Bayrakçı ,&nbsp;İvo Gökmen ,&nbsp;Elif Mercan Demirtaş ,&nbsp;Didem Divriklioğlu ,&nbsp;Tayyip İlker Aydın ,&nbsp;Muhammet Bekir Hacıoğlu","doi":"10.1016/j.clgc.2025.102459","DOIUrl":"10.1016/j.clgc.2025.102459","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>What is already known about this topic?</div><div>Paratesticular spindle cell rhabdomyosarcoma (RMS) is an extremely rare histological subtype of soft tissue sarcoma in adults. Most available data come from pediatric populations, and adult cases are limited to sporadic case reports. Due to its rarity, there is no consensus on the optimal management strategy for adult patients.</div></span></li><li><span>•</span><span><div>What this study adds?</div><div>This case report presents a rare adult patient with paratesticular spindle cell RMS, highlighting the diagnostic challenges, pathological features, and treatment course, including surgery and adjuvant chemotherapy. By comparing this case with previously reported adult cases in the literature, this study provides valuable insights into prognosis and therapeutic approaches for this uncommon entity in adults.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102459"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145519001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity Comparison between a Four-Week Moderate Hypofractionation and a Six-Week Conventional Fractionation in the Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer","authors":"Ha Un Kim ,&nbsp;Jaeha Lee ,&nbsp;Yoon Young Jo ,&nbsp;Sumin Lee ,&nbsp;Yeon Joo Kim","doi":"10.1016/j.clgc.2025.102473","DOIUrl":"10.1016/j.clgc.2025.102473","url":null,"abstract":"<div><h3>Introduction</h3><div>We compared toxicity profiles of moderate hypofractionated radiotherapy (HFRT) and conventional radiotherapy (CFRT) in salvage radiotherapy (SRT) for prostate cancer patients who underwent radical prostatectomy.</div></div><div><h3>Patients and Methods</h3><div>We retrospectively reviewed prostate cancer patients who underwent SRT between 2022 and 2023. Two groups were analyzed: CFRT (66 Gy in 30 fractions) and HFRT (55 Gy in 20 fractions). Propensity score matching was performed using variables associated with toxicity outcomes including androgen deprivation therapy usage, anticoagulant usage, diabetes mellitus, baseline genitourinary symptoms, SRT field, and boost irradiation. Follow-up evaluations were conducted every 3 months for the first year and every 6 months thereafter, for up to 2 years. The primary endpoint was acute and late genitourinary (GU) and gastrointestinal (GI) toxicity.</div></div><div><h3>Results</h3><div>A total of 70 CFRT and 66 HFRT patients were included. After matching, 112 patients (56 per group) were analyzed with median follow-up of 27.8 and 24.8 months, respectively. There was no significant difference in baseline toxicities before SRT between the 2 groups. GU toxicities at 3 months were comparable except for grade 1 urgency, which was more frequent in CFRT (30.4% vs. 14.3%, <em>P</em> = .041) but resolved by 1 year. Late GU toxicities at 1 or 2 years were not significantly different between the 2 groups. No grade ≥ 3 late GU toxicities were observed. For GI toxicities, grade 3 rectal bleeding occurred in 3.6% of CFRT and 1.8% of HFRT patients within 1 year (<em>P</em> = 1.000). Aside from more grade 2 diarrhea at 3 months in CFRT (26.8% vs. 8.9%, <em>P</em> = .014), no significant differences in GI toxicity were found.</div></div><div><h3>Conclusion</h3><div>Four-week HFRT for SRT showed favorable long-term toxicity outcomes, sustained for up to 2 years and comparable to those of 6-week CFRT.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102473"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transperineal versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Caio Vinicius Suartz ,&nbsp;Lucas Amorim Santos ,&nbsp;Caio Felipe Araujo Matalani ,&nbsp;Vinícius DallAqua ,&nbsp;Leonam Bringhenti Schumacher ,&nbsp;Henrique Laurent Lepine ,&nbsp;José Bessa Júnior ,&nbsp;Walid Shahrour ,&nbsp;Walid Shabana ,&nbsp;Leonardo Oliveira Reis ,&nbsp;Bárbara Vieira Lima Aguiar ,&nbsp;Maurício Dener Cordeiro ,&nbsp;William Carlos Nahas ,&nbsp;Leopoldo Alves Ribeiro-Filho","doi":"10.1016/j.clgc.2025.102467","DOIUrl":"10.1016/j.clgc.2025.102467","url":null,"abstract":"<div><div>To compare the safety and diagnostic performance of transperineal (TP) versus transrectal (TR) ultrasound-guided prostate biopsies using only data from randomized controlled trials (RCTs). A systematic search was performed in multiple databases up to May 2025. We included only RCTs comparing TP and TR approaches in men undergoing MRI-targeted prostate biopsies. Meta-analysis was conducted using odds ratios (OR) and 95% confidence intervals (CI) for categorical outcomes. The primary endpoints were cancer detection rate and postbiopsy infection rate. Secondary outcomes included urinary retention, bleeding, pain, and complications stratified by the Clavien–Dindo system. Study quality and certainty of evidence were assessed using the Cochrane ROB2 and GRADE tools. Four RCTs encompassing 2682 patients (TP: 1323; TR: 1359) were included. No significant differences were observed in overall prostate cancer detection rates (OR 1.03, 95% CI, 0.79-1.36) or detection of anterior lesions (OR 1.01, 95% CI, 0.41-2.45). Similarly, no differences were found in bleeding (OR 1.14, 95% CI, 0.66-1.95), urinary retention (OR 1.01, 95% CI, 0.50-2.04), total infections (OR 1.02, 95% CI, 0.77-1.35), or severe infections (OR 2.17, 95% CI, 0.97-4.88). Mild pain was more frequent in the TP group (OR 1.56, 95% CI, 1.20-2.03), while moderate to severe pain did not differ significantly (OR 0.65, 95% CI, 0.39-1.07). Transperineal and transrectal MRI–fusion–guided biopsy approaches demonstrated equivalent diagnostic accuracy and safety profiles. While the transperineal route was associated with slightly greater mild discomfort, cancer detection and complication rates were comparable. The selection of approach should be guided by principles of antimicrobial stewardship, patient preference, and institutional expertise.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102467"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second Malignancies and Non-Cancer Mortality in Long-Term Survivors of Stage I Testicular Cancer: A 30-Year Institutional Experience and Literature Review","authors":"Patricia Capdevila,&nbsp;Jorge Aparicio","doi":"10.1016/j.clgc.2025.102475","DOIUrl":"10.1016/j.clgc.2025.102475","url":null,"abstract":"<div><h3>Purpose</h3><div>To quantify long-term, competing-risk–adjusted absolute risks of non–germ-cell second malignant neoplasms and contralateral germ-cell tumor in stage I testicular germ-cell tumor survivors treated in the contemporary era, and to contextualize these estimates against prior population-based cohorts.</div></div><div><h3>Methods</h3><div>Retrospective single-center cohort of consecutive stage I TGCT (1994-2023); time zero was orchiectomy. Primary endpoints were time to first non–germ-cell SMN and to contralateral TGCT (cGCT). Death was modeled as a competing event. Absolute risks were estimated with the Aalen–Johansen cumulative incidence function (CIF) with 95% CIs; follow-up by reverse Kaplan–Meier. CIFs were compared by initial strategy (surveillance vs. adjuvant therapy) using Gray’s test.</div></div><div><h3>Results</h3><div>Among 169 survivors, SMN occurred in 9 (5.3%; median latency 9.4 y) and cGCT in 8 (4.7%; median 7.7 y). The 10-year CIFs were 3.7% (95% CI, 0.7-7.2) for SMN and 4.6% (1.4-8.8) for cGCT; by 25 years, 11.1% (3.6-20.9) and 8.4% (2.9-16.8), respectively. There were no TGCT-related deaths; overall mortality was 5.3% (3 SMN-related; 6 non-cancer). No clear difference emerged between surveillance and adjuvant therapy (SMN, Gray’s <em>P</em> = .9; cGCT curves overlapped).</div></div><div><h3>Conclusions</h3><div>In a contemporary, stage I cohort with long-term follow-up, late events were driven by competing risks. Absolute risks of late events were modest but clinically relevant (SMN ≈ 11% and cGCT ≈ 8% by 25 years), lower than historical series treated with high-dose radiotherapy.</div></div><div><h3>Implications for Cancer Survivors</h3><div>Our findings support survivorship plans that prioritize targeted second-cancer screening, cardiometabolic prevention with early postcisplatin vigilance, and proactive mental-health support, while maintaining a minimum-effective-dose approach to initial and follow-up treatments.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102475"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Enfortumab Vedotin ± Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma","authors":"Martin Kurian ,&nbsp;Ronac Mamtani ,&nbsp;Omar Elghawy ,&nbsp;Vivek Nimgaonkar","doi":"10.1016/j.clgc.2025.102474","DOIUrl":"10.1016/j.clgc.2025.102474","url":null,"abstract":"<div><h3>Introduction</h3><div>Enfortumab vedotin (EV) in combination with pembrolizumab (P) is the first-line treatment for advanced urothelial carcinoma, but real-world toxicity profiles and associations with survival remain an area of active investigation.</div></div><div><h3>Patients and Methods</h3><div>Here, we first perform a single-center (University of Pennsylvania) retrospective study of EV ± P patients to characterize frequency and clinical importance of 5 relevant toxicities (skin reaction, neuropathy, ocular disorder, hyperglycemia, and pneumonitis). We associate these toxicities with survival and then evaluate these findings in a larger national cohort (Flatiron Health Research Database [FHRD]).</div></div><div><h3>Results</h3><div>We find that toxicities were common in the single-center cohort, with skin reaction (60%) and neuropathy (47%) most frequent, but toxicity-related discontinuation or hospitalization were less frequent (13%). Without a landmark analysis, multiple toxicities were linked to survival, but landmark analysis to address immortal time bias preserved only the skin reaction-survival association (Penn: HR = 0.28, 95% CI, 0.14-0.58; FHRD: HR = 0.69, 95% CI, 0.53-0.90).</div></div><div><h3>Conclusions</h3><div>These findings highlight the clinical relevance of EV ± P related toxicities, demonstrate the importance of accounting for immortal time bias in associations of these toxicities with survival, and add to a growing evidence base showing a survival association with skin toxicity in EV ± P treated patients. Future prospective studies are needed to evaluate skin toxicity as a favorable marker for survival.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102474"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use","authors":"Tobias Peres,&nbsp;James Larkin","doi":"10.1016/j.clgc.2025.102470","DOIUrl":"10.1016/j.clgc.2025.102470","url":null,"abstract":"<div><h3>Background and Objective</h3><div>To evaluate the efficacy and toxicity of ipilimumab and nivolumab in advanced clear cell renal cell carcinoma (ccRCC) and rare variant RCC, and assess the impact of immune-related adverse events (irAEs) and steroid use on survival.</div></div><div><h3>Methods</h3><div>This retrospective study included patients with advanced ccRCC and rare variant RCC treated with first-line ipilimumab and nivolumab at the Royal Marsden Hospital between 2016 and 2025. Survival, toxicity, and the impact of irAEs and steroid use were analyzed using landmark and time-dependent methods.</div></div><div><h3>Key Findings and Limitations</h3><div>Among 154 patients, 35 had rare variant RCC and 18 had brain metastases (BM). Median follow-up was 20.3 months (ccRCC) and 24.2 months (rare variants). Median overall survival (OS) was 31.9 months (95% CI, 23.5-59.1) for ccRCC and 25.9 months (95% CI, 21.9-not estimable (NE)) for rare variants. Median progression-free survival (PFS) was 9.0 months (95% CI, 7.1-12.8) and 7.2 months (95% CI, 4.6-NE), respectively. Objective response rates (ORR) were 41.0% (ccRCC) and 38.2% (rare variants). In BM patients, median OS was 14.5 months (95% CI, 8.3-NE), PFS 6.2 months (95% CI, 3.3-NE), and ORR 27.8%. Grade 3–4 irAEs occurred in 28.4% and were associated with longer OS at 6-week landmark (NR vs. 23.1 months, <em>P</em> = .033). Prednisone ≥ 40 mg was associated with improved OS (61.2 vs. 22.3 months, <em>P</em> = .021), confirmed on multivariable analysis. Limitations include small sample size and retrospective design.</div></div><div><h3>Conclusions and Clinical Implications</h3><div>Ipilimumab and nivolumab demonstrated real-world efficacy in both ccRCC and rare variant RCC. Grade 3–4 irAEs and the use of high-dose steroids for their management were associated with improved OS.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102470"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Malignancy After EBRT: A Closer Look at Absolute Risk and Follow-Up","authors":"Ahmet Necati Sanli ,&nbsp;Deniz Esin Tekcan Sanli","doi":"10.1016/j.clgc.2025.102479","DOIUrl":"10.1016/j.clgc.2025.102479","url":null,"abstract":"","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102479"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer","authors":"Jasper P. Hof ,&nbsp;Lambertus A.L.M. Kiemeney ,&nbsp;Katja K.H. Aben ,&nbsp;Antoine G. van der Heijden ,&nbsp;Alina Vrieling ,&nbsp;Sita H. Vermeulen","doi":"10.1016/j.clgc.2025.102464","DOIUrl":"10.1016/j.clgc.2025.102464","url":null,"abstract":"<div><h3>Aim</h3><div>Patients with NMIBC frequently experience recurrences. Yet, the timing and characteristics of subsequent recurrences are understudied. We aim to describe subsequent recurrences in a large, contemporary, population-based cohort.</div></div><div><h3>Methods</h3><div>We included 1915 patients from the UroLife study and the Nijmegen Bladder Cancer Study, diagnosed with primary NMIBC between 2011 and 2021. The conditional 1-, 3- and 5-year risks of first to fourth recurrence were calculated using Kaplan–Meier risks, stratified by clinicopathological factors. Patterns of subsequent tumors were described and visualized.</div></div><div><h3>Results</h3><div>We observed 671 first recurrences and 400 subsequent recurrences. The 3-year conditional recurrence risks for first, second and third recurrence were 31%, 45%, and 54%, respectively, and were similar for NMIBC risk groups. Recurrence after a low-, intermediate- or high-risk tumor (either primary or recurrent) was again of low-, intermediate- or high-risk in 74%, 62% and 44% of cases, respectively. Ten patients with low/intermediate-risk NMIBC and 89 patients with high-risk NMIBC progressed to MIBC or mBC. Seven out of these ten (70%) and 13 out of these 89 (15%) patients had a high-risk recurrence before progression. This study was limited to a patient cohort from The Netherlands.</div></div><div><h3>Conclusions</h3><div>Our study provides reliable estimates of recurrence rates and patterns in NMIBC from a large, contemporary, population-based cohort. Recurring NMIBC tumors often exhibit similar clinicopathological characteristics, and patients with primary low- or intermediate-risk NMIBC that progresses to MIBC/mBC often have a high-risk recurrence before progression. These results can inform research into NMIBC recurrences and surveillance schedules.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102464"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145621543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma","authors":"Ryan D. Chow,&nbsp;Ronac Mamtani","doi":"10.1016/j.clgc.2025.102417","DOIUrl":"10.1016/j.clgc.2025.102417","url":null,"abstract":"<div><h3>Background</h3><div>Combination therapy with enfortumab vedotin plus pembrolizumab (EV+P) is now the preferred first-line (1L) therapy for advanced urothelial carcinoma (aUC), but prognostic indicators for patients on 1L EV+P have not yet been described.</div></div><div><h3>Patients and Methods</h3><div>We conducted a retrospective cohort study of patients receiving 1L EV+P for aUC. We analyzed deidentified electronic health record data from the Flatiron Health database to identify adults with aUC who initiated EV+P between April 3, 2023 and December 31, 2024. Inclusion required absence of death, disease progression, or second line therapy start within 30 days of EV+<em>P</em> initiation, as well as documented weight measurements at the time of EV+P initiation (i.e., day 0) and day 28. We used Cox proportional hazards modeling with stabilized inverse probability treatment weighting (IPTW) to evaluate the association of early on-treatment weight loss with overall survival (OS), progression-free survival (PFS), and time to EV discontinuation.</div></div><div><h3>Results</h3><div>A total of 401 patients met study criteria. Of these, 78 patients (19.5%) experienced ≥ 5% weight loss by day 28 following EV+P initiation. Early on-treatment weight loss was associated with inferior OS (median 12.8 vs. 20.4 months; IPTW-adjusted HR [aHR] = 2.04 [1.41-2.95], <em>P</em> = 1.9 × 10^-4), but not with PFS (aHR = 1.22 [0.89-1.65], <em>P</em> = .22) or time to EV discontinuation (aHR = 1.30 [0.96-1.77], <em>P</em> = .090). The association of early on-treatment weight loss with OS was conserved in subgroup analyses stratifying patients by baseline albumin or BMI.</div></div><div><h3>Conclusion</h3><div>Early weight loss ≥5% occurred in one fifth of patients receiving 1L EV+P treatment and was associated with inferior overall survival.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 6","pages":"Article 102417"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenia in mCSPC: Beyond Radiological Metrics—The Need for Functional and Supportive Assessments","authors":"Cevat İlteriş Kıkılı ,&nbsp;Maide Müreva ,&nbsp;Caner Kapar ,&nbsp;Bahadır Köylü ,&nbsp;Fatih Kemik ,&nbsp;Feyyaz Hazar Yağmur ,&nbsp;Fatih Selçukbiricik ,&nbsp;Ercan İnci ,&nbsp;Deniz Tural","doi":"10.1016/j.clgc.2025.102440","DOIUrl":"10.1016/j.clgc.2025.102440","url":null,"abstract":"","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 6","pages":"Article 102440"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}